OrbiMed Launches $600 Million Royalty Opportunities Fund

NEW YORK, Aug 31, 2011 (BUSINESS WIRE) -- OrbiMed, a leading investment management firm focused on the healthcare sector, today announced the final closing of a new fund that acquires healthcare royalty streams and provides structured debt capital to healthcare companies. The fund, the "Royalty Opportunities S.ar.l.", is domiciled in Luxembourg and will invest worldwide to take advantage of OrbiMed's global platform. Investors in the $600 million fund include some of the largest endowments, foundations and financial institutions globally.

OrbiMed has dedicated significant resources and personnel to support the new fund, including three OrbiMed Partners, Samuel D. Isaly, Sven H. Borho and W. Carter Neild, along with a dedicated team of four professionals: Tadd S. Wessel, Matthew S. Rizzo, Matthew L. Wotiz and J. Christopher LiPuma.

"Life sciences companies are typically dependent on equity markets to raise new capital," observed Tadd Wessel, a Managing Director on the Royalty Opportunities team. "With this fund, OrbiMed can offer a minimally dilutive capital alternative to fund product launches, M&A opportunities, new product research, and general corporate purposes."

"We welcome the opportunity to discuss with owners of royalty streams the potential to monetize those future cash flows in order to meet their financial objectives, from companies seeking to increase R&D, research institutions seeking new facilities, or individual inventors seeking liquidity," noted Matthew Rizzo, also a Managing Director on the Royalty team.

OrbiMed's Royalty team can be reached at (212) 739-6400.

About OrbiMed

OrbiMed Advisors LLC is a leading investment firm dedicated exclusively to the healthcare sector, with over $5 billion in assets under management. OrbiMed invests across the entire spectrum of healthcare companies on a worldwide basis. Investments are made through private equity funds, hedge funds, royalty funds, and other investment vehicles.

OrbiMed's investment team includes over 50 experienced professionals with offices in New York City, San Francisco, Shanghai, Mumbai and Israel. As the largest investment firm solely dedicated to the healthcare sector, OrbiMed is a capital provider of choice, bringing the global resources required to be an exceptional long-term partner for building world-class healthcare companies. www.OrbiMed.com .

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.